As always focused on the research highlight of antibody discovery, Creative Biolabs has launched a series of IVD (in vitro diagnostic) antibody development services targeting novel and potential biomarkers of various cancer diseases, such as colorectal cancer. Especially, we can develop antibodies target the Ezrin marker to help diagnose colorectal cancer. A team of experienced scientists focused on IVD antibody development are willing to support your IVD antibody discovery requirements in a timely and cost-effective method.
Ezrin, also known as cytovillin or villin-2, is a cytoplasmic peripheral protein that in humans is encoded by the EZR gene. Ezrin belongs to the Ezrin-Radoxin-Moesin (ERM) protein family. ERM proteins play a role in microvilli formation and breakdown and are also essential for cell-cell and cell-substrate adhesions. Ezrin can be phosphorylated by the protein-tyrosine kinase in microvilli and acts as a critical nexus between the actin cytoskeleton and plasma membrane. Besides, this cell cortex plays an essential role in cell surface structure adhesion, organization, and migration. Ezrin can also interact with the membrane via the peripheral protein EBP50, a PDZ domain-containing protein. What’s more, Ezrin has shown to be implicated in a variety of human cancers.
Colorectal cancer (CRC) remains the third most common malignancy among females and males worldwide, although the progress has been made in the diagnostic and the therapeutic method. Therefore, more sensitive CRC biomarkers that allow to predict prognosis and guide effective targeting therapy should be investigated. Ezrin protein is involved in the regulation of cytoskeletal and directly impacts survival and tumor progression. It is involved in the invasion, metastasis, and clinical prognosis in several types of cancer. The expression of Ezrin has been reported to be increased in both metastatic cells and tissues in several types of cancer including colorectal cancer. A previous study has shown that a higher cytoplasmatic ezrin expression is associated with higher tumor aggressiveness and a worse prognosis in CCR patients.
Fig.1 Images of Ezrin Immunoreactivity in Colorectal Adenocarcinoma: A. negative staining in malignant cells; B. weak cytoplasmic positivity; C. moderate cytoplasmic positivity; and D. strong cytoplasmic positivity. (Patara, M., 2011)
Based on current findings, the Ezrin protein may be an important target for anti-metastatic therapies and its expression is a significant prognostic marker for colorectal cancer. Creative Biolabs, a world-leading service provider in the field of IVDs, offers the most comprehensive IVD antibody development services targeting Ezrin to our worldwide clients, based on our advanced technologies and unparalleled expertise.
Our services are flexible to meet your specific requirements, we can develop antibodies to fit different immunoassay formats, including ELISAs, immunohistochemistry, western blot, etc. Please feel free to contact us to get more information.
Reference
For Research Use Only.
